{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:10:56Z","timestamp":1782835856313,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":131,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32000492"],"award-info":[{"award-number":["32000492"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170736"],"award-info":[{"award-number":["32170736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92357301"],"award-info":[{"award-number":["92357301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hong Kong Research Grant Council","award":["Research Fellow Scheme #RFS2021-2S01"],"award-info":[{"award-number":["Research Fellow Scheme #RFS2021-2S01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Taxane-based chemotherapy is a main treatment modality for ovarian cancer and other solid tumors, but chemoresistance limits the clinical efficacy. Studies have shown tumor interaction with macrophages in the tumor microenvironment (TME) plays a significant role in taxane resistance, yet the underlying molecular mechanisms are poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we employed translatome profiling of paclitaxel-treated cancer cells, live-cell imaging analysis, gene knockdown\/knockout, and in vitro cancer-macrophage coculture assays to unravel a novel chemoresistance mechanism mediated by tumor-macrophage interaction via the NOTCH2-JAG1 axis. The in vitro data were further validated by multiple xenograft, syngeneic and patient-derived xenograft mouse tumor models of ovarian cancer as well as ovarian cancer patient samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found paclitaxel selectively induced translational upregulation of NOTCH2 via cytoplasmic polyadenylation, and this NOTCH2 upregulation persisted after mitotic exit. Subsequent NOTCH2 activation by JAG1 expressed mainly on the neighboring macrophages promoted tumor cell survival and simulated cytokine release, such as CSF1 and IL-1\u03b2, that recruited JAG1-expressing macrophages, thus forming a positive feedback loop that further enhanced the pro-tumor NOTCH2 activity. Genetic depletion or pharmacological inhibition of NOTCH2 with the \u03b3-secretase inhibitor attenuated macrophage infiltration and sensitized tumor response to paclitaxel in multiple preclinical models of ovarian cancer. Moreover, single-cell RNA sequencing analysis identified a JAG1-high macrophage subset that was enriched by paclitaxel treatment and attenuated by NOTCH inhibition. Clinically, high NOTCH2 expression in ovarian tumors was associated with recurrence and shorter progression-free survival of ovarian cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Paclitaxel-induced translational upregulation of NOTCH2 enables immediate juxtacrine activation by JAG1-positive macrophages, coupling tumor cell survival with immune remodeling in the tumor microenvironment to drive chemoresistance. Our results suggest NOTCH2 is a viable biomarker for paclitaxel resistance and that combining NOTCH2 inhibitor with taxane is an effective therapeutic strategy to selectively disrupt tumor-macrophage interaction and overcome macrophage-mediated taxane resistance in NOTCH2-positive tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02546-w","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T05:45:39Z","timestamp":1768023939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor-associated macrophages promote chemoresistance to Paclitaxel via activating NOTCH2-JAG1 juxtacrine signaling"],"prefix":"10.1186","volume":"25","author":[{"given":"Fazhi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"2546_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"2546_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/375424a0","volume":"375","author":"E Nogales","year":"1995","unstructured":"Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature. 1995;375:424\u20137.","journal-title":"Nature"},{"key":"2546_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253\u201365.","journal-title":"Nat Rev Cancer"},{"key":"2546_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.devcel.2004.09.002","volume":"7","author":"CL Rieder","year":"2004","unstructured":"Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell. 2004;7:637\u201351.","journal-title":"Dev Cell"},{"key":"2546_CR5","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA. How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677\u201381.","journal-title":"Mol Biol Cell"},{"key":"2546_CR6","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1038\/onc.2011.30","volume":"30","author":"A Janssen","year":"2011","unstructured":"Janssen A, Medema RH. Mitosis as an anti-cancer target. Oncogene. 2011;30:2799\u2013809.","journal-title":"Oncogene"},{"key":"2546_CR7","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/0008-5472.CAN-07-6699","volume":"68","author":"J Shi","year":"2008","unstructured":"Shi J, Orth JD, Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res. 2008;68:3269\u201376.","journal-title":"Cancer Res"},{"key":"2546_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccr.2008.07.002","volume":"14","author":"KE Gascoigne","year":"2008","unstructured":"Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 2008;14:111\u201322.","journal-title":"Cancer Cell"},{"key":"2546_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1083\/jcb.200906150","volume":"186","author":"Z Yang","year":"2009","unstructured":"Yang Z, Kenny AE, Brito DA, Rieder CL. Cells satisfy the mitotic checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic attachments. J Cell Biol. 2009;186:675\u201384.","journal-title":"J Cell Biol"},{"key":"2546_CR10","doi-asserted-by":"publisher","first-page":"T83","DOI":"10.1530\/ERC-17-0003","volume":"24","author":"J Shi","year":"2017","unstructured":"Shi J, Mitchison TJ. Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocr Relat Cancer. 2017;24:T83\u201396.","journal-title":"Endocr Relat Cancer"},{"key":"2546_CR11","doi-asserted-by":"publisher","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Reviews Disease Primers. 2016;2:16061.\u00a0https:\/\/doi.org\/10.1038\/nrdp.2016.61.","DOI":"10.1038\/nrdp.2016.61"},{"key":"2546_CR12","doi-asserted-by":"publisher","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, Tang Q, Li Q, Zhang C, Wang H, Zou D. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23:66.\u00a0https:\/\/doi.org\/10.1186\/s12943-024-01967-3.","DOI":"10.1186\/s12943-024-01967-3"},{"key":"2546_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","volume":"86","author":"E Schoutrop","year":"2022","unstructured":"Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Sem Cancer Biol. 2022;86:207\u201323.","journal-title":"Sem Cancer Biol"},{"key":"2546_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molmed.2020.09.007","volume":"27","author":"S Rodrigues-Ferreira","year":"2021","unstructured":"Rodrigues-Ferreira S, Moindjie H, Haykal MM, Nahmias C. Predicting and overcoming taxane chemoresistance. Trends Mol Med. 2021;27:138\u201351.","journal-title":"Trends Mol Med"},{"key":"2546_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrc2803","volume":"10","author":"M Kavallaris","year":"2010","unstructured":"Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194\u2013204.","journal-title":"Nat Rev Cancer"},{"key":"2546_CR16","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ncb3231","volume":"17","author":"E Domenech","year":"2015","unstructured":"Domenech E, Maestre C, Esteban-Martinez L, Partida D, Pascual R, Fernandez-Miranda G, Seco E, Campos-Olivas R, Perez M, Megias D, et al. AMPK and PFKFB3 mediate Glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol. 2015;17:1304\u201316.","journal-title":"Nat Cell Biol"},{"key":"2546_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccell.2015.05.009","volume":"28","author":"Y Yu","year":"2015","unstructured":"Yu Y, Gaillard S, Phillip JM, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, et al. Inhibition of spleen tyrosine kinase potentiates Paclitaxel-Induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell. 2015;28:82\u201396.","journal-title":"Cancer Cell"},{"key":"2546_CR18","doi-asserted-by":"publisher","first-page":"11150","DOI":"10.1038\/ncomms11150","volume":"7","author":"CL Au Yeung","year":"2016","unstructured":"Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, et al. Exosomal transfer of stroma-derived miR21 confers Paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150.","journal-title":"Nat Commun"},{"key":"2546_CR19","doi-asserted-by":"publisher","first-page":"13316","DOI":"10.1038\/s41598-019-49649-1","volume":"9","author":"J Yang","year":"2019","unstructured":"Yang J, Zaman MM, Vlasakov I, Roy R, Huang L, Martin CR, Freedman SD, Serhan CN, Moses MA. Adipocytes promote ovarian cancer chemoresistance. Sci Rep. 2019;9:13316.","journal-title":"Sci Rep"},{"key":"2546_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54\u201367.","journal-title":"Cancer Discov"},{"key":"2546_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ccr.2014.04.026","volume":"25","author":"NI Affara","year":"2014","unstructured":"Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014;25:809\u201321.","journal-title":"Cancer Cell"},{"key":"2546_CR22","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","volume":"75","author":"R Hughes","year":"2015","unstructured":"Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 2015;75:3479\u201391.","journal-title":"Cancer Res"},{"key":"2546_CR23","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1101\/gad.180331.111","volume":"25","author":"T Shree","year":"2011","unstructured":"Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25:2465\u201379.","journal-title":"Genes Dev"},{"key":"2546_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"key":"2546_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.molcel.2016.04.007","volume":"62","author":"JE Park","year":"2016","unstructured":"Park JE, Yi H, Kim Y, Chang H, Kim VN. Regulation of Poly(A) tail and translation during the somatic cell cycle. Mol Cell. 2016;62:462\u201371.","journal-title":"Mol Cell"},{"key":"2546_CR26","doi-asserted-by":"publisher","unstructured":"Tanenbaum ME, Stern-Ginossar N, Weissman JS, Vale RD. Regulation of mRNA translation during mitosis. Elife 2015, 4:e07957. https:\/\/doi.org\/10.7554\/eLife.07957}","DOI":"10.7554\/eLife.07957"},{"key":"2546_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.15252\/embj.201385162","volume":"34","author":"N Ozlu","year":"2015","unstructured":"Ozlu N, Qureshi MH, Toyoda Y, Renard BY, Mollaoglu G, Ozkan NE, Bulbul S, Poser I, Timm W, Hyman AA, et al. Quantitative comparison of a human cancer cell surface proteome between interphase and mitosis. EMBO J. 2015;34:251\u201365.","journal-title":"EMBO J"},{"key":"2546_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fonc.2018.00518","volume":"8","author":"EWJ Mollen","year":"2018","unstructured":"Mollen EWJ, Ient J, Tjan-Heijnen VCG, Boersma LJ, Miele L, Smidt ML, Vooijs M. Moving breast cancer therapy up a Notch. Front Oncol. 2018;8:518.","journal-title":"Front Oncol"},{"key":"2546_CR29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2018.07.009","volume":"34","author":"O Meurette","year":"2018","unstructured":"Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34:536\u201348.","journal-title":"Cancer Cell"},{"key":"2546_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41573-020-00091-3","volume":"20","author":"S Majumder","year":"2021","unstructured":"Majumder S, Crabtree JS, Golde TE, Minter LM, Osborne BA, Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov. 2021;20:125\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"2546_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/ncb2046","volume":"12","author":"I Novoa","year":"2010","unstructured":"Novoa I, Gallego J, Ferreira PG, Mendez R. Mitotic cell-cycle progression is regulated by CPEB1 and CPEB4-dependent translational control. Nat Cell Biol. 2010;12:447\u201356.","journal-title":"Nat Cell Biol"},{"key":"2546_CR32","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-14-0969","volume":"14","author":"T Voloshin","year":"2015","unstructured":"Voloshin T, Alishekevitz D, Kaneti L, Miller V, Isakov E, Kaplanov I, Voronov E, Fremder E, Benhar M, Machluf M, et al. Blocking IL1beta pathway following Paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol Cancer Ther. 2015;14:1385\u201394.","journal-title":"Mol Cancer Ther"},{"key":"2546_CR33","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","volume":"187","author":"Y Luo","year":"2024","unstructured":"Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, Zhou D, Dong Y, Li X, Qian Y, et al. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187:4905\u2013e49254924.","journal-title":"Cell"},{"key":"2546_CR34","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet (London England). 2019;393:1240\u201353.","journal-title":"Lancet (London England)"},{"key":"2546_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1126\/science.1231041","volume":"340","author":"X Wang","year":"2013","unstructured":"Wang X, Ha T. Defining single molecular forces required to activate integrin and Notch signaling. Sci (New York NY). 2013;340:991\u20134.","journal-title":"Sci (New York NY)"},{"key":"2546_CR36","doi-asserted-by":"publisher","unstructured":"Wang M, Han X, Liu C, Takayama R, Yasugi T, Ei SI, Nagayama M, Tanaka Y, Sato M. Intracellular trafficking of Notch orchestrates temporal dynamics of Notch activity in the fly brain. Nat Commun. 2021;12:2083. https:\/\/doi.org\/10.1038\/s41467-021-22442-3.","DOI":"10.1038\/s41467-021-22442-3"},{"key":"2546_CR37","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-19-0596","volume":"79","author":"M Song","year":"2019","unstructured":"Song M, Ping Y, Zhang K, Yang L, Li F, Zhang C, Cheng S, Yue D, Maimela NR, Qu J, et al. Low-Dose IFNgamma induces tumor cell stemness in tumor microenvironment of Non-Small cell lung cancer. Cancer Res. 2019;79:3737\u201348.","journal-title":"Cancer Res"},{"key":"2546_CR38","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2011-04-348706","volume":"119","author":"L Scheppke","year":"2012","unstructured":"Scheppke L, Murphy EA, Zarpellon A, Hofmann JJ, Merkulova A, Shields DJ, Weis SM, Byzova TV, Ruggeri ZM, Iruela-Arispe ML, Cheresh DA. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood. 2012;119:2149\u201358.","journal-title":"Blood"},{"key":"2546_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.devcel.2017.02.009","volume":"40","author":"O Shaya","year":"2017","unstructured":"Shaya O, Binshtok U, Hersch M, Rivkin D, Weinreb S, Amir-Zilberstein L, Khamaisi B, Oppenheim O, Desai RA, Goodyear RJ, et al. Cell-Cell contact area affects Notch signaling and Notch-Dependent patterning. Dev Cell. 2017;40:505\u2013e511506.","journal-title":"Dev Cell"},{"key":"2546_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462\u201372.","journal-title":"Cancer Cell"},{"key":"2546_CR41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43:546\u201363.","journal-title":"Trends Immunol"},{"key":"2546_CR42","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-15-0242","volume":"21","author":"D Cui","year":"2015","unstructured":"Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET. Notch pathway Inhibition using PF-03084014, a gamma-Secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. Clin Cancer Res. 2015;21:4619\u201329.","journal-title":"Clin Cancer Res"},{"key":"2546_CR43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pharmthera.2013.09.005","volume":"141","author":"N Takebe","year":"2014","unstructured":"Takebe N, Nguyen D, Yang SX. Targeting Notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141:140\u20139.","journal-title":"Pharmacol Ther"},{"key":"2546_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","volume":"137","author":"I Diaz-Padilla","year":"2015","unstructured":"Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015;137:216\u201322.","journal-title":"Gynecol Oncol"},{"key":"2546_CR45","doi-asserted-by":"publisher","unstructured":"Zhdanovskaya N, Firrincieli M, Lazzari S, Pace E, Scribani Rossi P, Felli MP, Talora C, Screpanti I, Palermo R. Targeting Notch to maximize chemotherapeutic benefits: Rationale, advanced Strategies, and future perspectives. Cancers (Basel). 2021;13(20):5106.\u00a0https:\/\/doi.org\/10.3390\/cancers13205106.","DOI":"10.3390\/cancers13205106"},{"key":"2546_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","volume":"22","author":"WK You","year":"2023","unstructured":"You WK, Schuetz TJ, Lee SH. Targeting the DLL\/Notch signaling pathway in cancer: challenges and advances in clinical development. Mol Cancer Ther. 2023;22:3\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2546_CR47","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Schoffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, et al. Nirogacestat, a gamma-Secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898\u2013912.","journal-title":"N Engl J Med"},{"key":"2546_CR48","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1002\/cam4.2425","volume":"8","author":"ZI Hu","year":"2019","unstructured":"Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, et al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med. 2019;8:5148\u201357.","journal-title":"Cancer Med"},{"key":"2546_CR49","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1158\/1078-0432.CCR-14-2808","volume":"21","author":"WC Yen","year":"2015","unstructured":"Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, et al. Targeting Notch signaling with a Notch2\/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015;21:2084\u201395.","journal-title":"Clin Cancer Res"},{"key":"2546_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12943-025-02438-z","volume":"24","author":"S Dogra","year":"2025","unstructured":"Dogra S, Adhikari L, Benbrook DM, Bohn JA, Burgett A, Chandra V, Dockery L, Singh A, McNally L, Rai R, et al. Harnessing ovarian cancer Ascites for translational science: models, biomarkers, and therapeutics. Mol Cancer. 2025;24:257.","journal-title":"Mol Cancer"},{"key":"2546_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of Ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123:9\u201316.","journal-title":"Br J Cancer"},{"key":"2546_CR52","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-18-1176","volume":"18","author":"M Masiero","year":"2019","unstructured":"Masiero M, Li D, Whiteman P, Bentley C, Greig J, Hassanali T, Watts S, Stribbling S, Yates J, Bealing E, et al. Development of therapeutic Anti-JAGGED1 antibodies for cancer therapy. Mol Cancer Ther. 2019;18:2030\u201342.","journal-title":"Mol Cancer Ther"},{"key":"2546_CR53","doi-asserted-by":"publisher","unstructured":"Ingolia NT, Lareau LF, Weissman JSJC. Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell. 2011;147:789\u2013802.\u00a0https:\/\/doi.org\/10.1016\/j.cell.2011.10.002.","DOI":"10.1016\/j.cell.2011.10.002"},{"key":"2546_CR54","doi-asserted-by":"publisher","first-page":"16049","DOI":"10.1038\/celldisc.2016.49","volume":"3","author":"F Yu","year":"2017","unstructured":"Yu F, Jiang Y, Lu L, Cao M, Qiao Y, Liu X, Liu D, Van Dyke T, Wang F, Yao X, et al. Aurora-A promotes the establishment of spindle assembly checkpoint by priming the Haspin-Aurora-B feedback loop in late G2 phase. Cell Discov. 2017;3:16049.","journal-title":"Cell Discov"},{"key":"2546_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256\u201364.","journal-title":"Nat Struct Mol Biol"},{"key":"2546_CR56","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"2546_CR57","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood-2008-02-139725","volume":"113","author":"E Rosati","year":"2009","unstructured":"Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli A, Coaccioli S, Screpanti I, Marconi P. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113:856\u201365.","journal-title":"Blood"},{"key":"2546_CR58","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2018.01.002","volume":"172","author":"N Nandagopal","year":"2018","unstructured":"Nandagopal N, Santat LA, LeBon L, Sprinzak D, Bronner ME, Elowitz MB. Dynamic ligand discrimination in the Notch signaling pathway. Cell. 2018;172:869\u2013e880819.","journal-title":"Cell"},{"key":"2546_CR59","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-18-3397","volume":"79","author":"T Yin","year":"2019","unstructured":"Yin T, Zhao ZB, Guo J, Wang T, Yang JB, Wang C, Long J, Ma S, Huang Q, Zhang K, et al. Aurora A Inhibition eliminates myeloid Cell-Mediated immunosuppression and enhances the efficacy of Anti-PD-L1 therapy in breast cancer. Cancer Res. 2019;79:3431\u201344.","journal-title":"Cancer Res"},{"key":"2546_CR60","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1158\/2159-8290.CD-17-0037","volume":"7","author":"Q Shen","year":"2017","unstructured":"Shen Q, Cohen B, Zheng W, Rahbar R, Martin B, Murakami K, Lamorte S, Thompson P, Berman H, Zuniga-Pflucker JC, et al. Notch shapes the innate immunophenotype in breast cancer. Cancer Discov. 2017;7:1320\u201335.","journal-title":"Cancer Discov"},{"key":"2546_CR61","doi-asserted-by":"publisher","unstructured":"Feng D, Xiang X, Guan Y, Guillot A, Lu H, Chang C, He Y, Wang H, Pan H, Ju C et al. Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models. J Clin Invest. 2023;133(15):e166954.\u00a0https:\/\/doi.org\/10.1172\/JCI166954.","DOI":"10.1172\/JCI166954"},{"key":"2546_CR62","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","volume":"4","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wang X, Cheng X, Liu Z, Yin Y, Li X, Huang Z, Wang Z, Guo W, Ginhoux F, et al. Single-cell analyses implicate Ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nat Cancer. 2023;4:1138\u201356.","journal-title":"Nat Cancer"},{"key":"2546_CR63","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Paula C. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway. Cancer Cell. 2018;34:893\u2013e905898.","journal-title":"Cancer Cell"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02546-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:32:28Z","timestamp":1781627548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02546-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2546"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02546-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}